BR112022021893A2 - Métodos e combinações para o tratamento de câncer utilizando anticorpos inibidores de ponto de verificação imune - Google Patents

Métodos e combinações para o tratamento de câncer utilizando anticorpos inibidores de ponto de verificação imune

Info

Publication number
BR112022021893A2
BR112022021893A2 BR112022021893A BR112022021893A BR112022021893A2 BR 112022021893 A2 BR112022021893 A2 BR 112022021893A2 BR 112022021893 A BR112022021893 A BR 112022021893A BR 112022021893 A BR112022021893 A BR 112022021893A BR 112022021893 A2 BR112022021893 A2 BR 112022021893A2
Authority
BR
Brazil
Prior art keywords
combinations
methods
cancer
treatment
immune checkpoint
Prior art date
Application number
BR112022021893A
Other languages
English (en)
Portuguese (pt)
Inventor
Kurland John
Negro Alejandra
Chang Shao-Chun
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112022021893A2 publication Critical patent/BR112022021893A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR112022021893A 2020-05-12 2021-05-12 Métodos e combinações para o tratamento de câncer utilizando anticorpos inibidores de ponto de verificação imune BR112022021893A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063023554P 2020-05-12 2020-05-12
PCT/EP2021/062695 WO2021228978A1 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Publications (1)

Publication Number Publication Date
BR112022021893A2 true BR112022021893A2 (pt) 2022-12-20

Family

ID=75977756

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021893A BR112022021893A2 (pt) 2020-05-12 2021-05-12 Métodos e combinações para o tratamento de câncer utilizando anticorpos inibidores de ponto de verificação imune

Country Status (12)

Country Link
US (3) US20220363762A1 (enExample)
EP (1) EP4021940A1 (enExample)
JP (2) JP7387912B2 (enExample)
KR (1) KR20230009354A (enExample)
CN (1) CN114729054A (enExample)
AU (3) AU2021269832B2 (enExample)
BR (1) BR112022021893A2 (enExample)
CA (1) CA3158607A1 (enExample)
IL (2) IL311936A (enExample)
MX (1) MX2022006728A (enExample)
TW (2) TW202535468A (enExample)
WO (1) WO2021228978A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054897A1 (en) * 2022-09-07 2024-03-14 The University Of Chicago Methods for treating cancer with hyperactive adar enzymes
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
AU2003221888B2 (en) 2002-04-11 2008-11-06 Medimmune, Llc Preservation of bioactive materials by spray drying
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
KR20100107083A (ko) 2002-12-17 2010-10-04 메디뮨 엘엘씨 생물활성 물질의 고압 분무 건조
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
MX389663B (es) * 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
HK1247578A1 (zh) * 2015-04-01 2018-09-28 Medimmune Limited 用於治疗非小细胞肺癌的组合抗pd-l1和抗ctla4抗体
US11214620B2 (en) * 2016-06-20 2022-01-04 F-Star Therapeutics Limited Binding molecules binding PD-L1 and LAG-3
CN109863402A (zh) * 2016-09-27 2019-06-07 鼎航医药股份有限公司 基于β2-糖蛋白1水平的用巴维昔单抗治疗癌症的方法和其测定
WO2018187227A1 (en) * 2017-04-03 2018-10-11 Concologie, Inc. Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
KR102693361B1 (ko) * 2017-05-26 2024-08-09 브루인 바이오사이언시스, 인크. 화학색전제
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
WO2019241742A1 (en) * 2018-06-14 2019-12-19 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
CA3102334A1 (en) * 2018-06-15 2019-12-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna

Also Published As

Publication number Publication date
JP2024016209A (ja) 2024-02-06
CA3158607A1 (en) 2021-11-18
AU2024202963A1 (en) 2024-05-30
KR20230009354A (ko) 2023-01-17
EP4021940A1 (en) 2022-07-06
US20210355224A1 (en) 2021-11-18
AU2024266949A1 (en) 2024-12-19
CN114729054A (zh) 2022-07-08
AU2024202963B2 (en) 2025-11-20
WO2021228978A1 (en) 2021-11-18
JP7387912B2 (ja) 2023-11-28
JP2023524359A (ja) 2023-06-12
TWI870592B (zh) 2025-01-21
IL297640A (en) 2022-12-01
US20220363762A1 (en) 2022-11-17
TW202535468A (zh) 2025-09-16
TW202207976A (zh) 2022-03-01
MX2022006728A (es) 2022-06-09
US20240239893A1 (en) 2024-07-18
IL311936A (en) 2024-06-01
AU2021269832B2 (en) 2024-09-19
AU2021269832A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CR20200467A (es) Agentes anticuerpos anti-cd25
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
BR112014018481A2 (pt) anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
BR112016030686A2 (pt) anticorpos anti tau humanizados
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
CO2022001195A2 (es) Anticuerpos dirigidos contra dll3 y usos de los mismos
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
BR112022024084A2 (pt) Receptores de antígeno quiméricos específicos para p95her2 e usos dos mesmos
BR112022021893A2 (pt) Métodos e combinações para o tratamento de câncer utilizando anticorpos inibidores de ponto de verificação imune
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
BR112021016398A2 (pt) Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer
BR112019004185A2 (pt) combinação de um anticorpo anti-cd20, inibidor de pi3-quinase-delta inibidor e anticorpo anti-pd-1 ou anti-pd-l1 para tratamento de cânceres hematológicos
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
BR112022001733A2 (pt) Anticorpos anti-ms4a4a e métodos de uso dos mesmos
JOP20210168A1 (ar) أجسام مضادة أحادية النسيلة ترتبط نوعيًا مع trbv9 بشري
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA202191666A1 (ru) Антитела к il-27 и их применение
BR112023006989A2 (pt) Anticorpos biespecíficos anti-pd-1/cd40 e usos dos mesmos
EA201990222A1 (ru) Антитела к o2 и пути их применения
BR112023014582A2 (pt) Método de tratamento do câncer
BR112022012362A2 (pt) Anticorpos cd163 ou proteínas de ligação
CL2023003047A1 (es) Anticuerpo anti componente del complemento 1s (c1s)
BR112022009147A2 (pt) Métodos de tratamento do câncer e métodos para aumentar, potencializar ou estimular uma resposta ou função imune

Legal Events

Date Code Title Description
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025009416-1 PROTOCOLO 870250038282 EM 12/05/2025 15:06.